Collegium Pharmaceutical, Inc. Deferred Income Tax Liabilities, Net
Collegium Pharmaceutical, Inc. (COLL) had Deferred Income Tax Liabilities, Net of $40.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Liabilities, Net $40.97M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $0.00; Deferred Income Tax Liabilities, Net as first filed $29.14M.
- 2024-12-31: Deferred Income Tax Liabilities, Net $54.19M.
- 2023-12-31: Deferred Income Tax Liabilities, Net $71.17M.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2026-06-30 | $40.97M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 | $29.14M 10-K · filed 2026-02-26 |
| 2024-12-31 | $54.19M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $71.17M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $94.54M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $5.00M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |